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Abstract
The complete blood count (CBC) is one of the most frequently requested tests in laboratory medicine, performed in a range of healthcare situations. 
The provision of an ideal assay material for external quality assessment is confounded by the fragility of the cellular components of blood, the lack of 
commutability of stabilised whole blood material and the lack of certified reference materials and methods to which CBC results can be traced. The 
choice of assay material between fresh blood, extended life assay material and fully stabilised, commercially prepared, whole blood material depen-
ds upon the scope and objectives of the EQA scheme. The introduction of new technologies in blood counting and the wider clinical application of 
parameters from the extended CBC will bring additional challenges for the EQA provider.
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Introduction
External Quality Assessment (EQA) or proficiency 
testing (PT) programmes are intended to allow 
medical laboratories or other testing sites to com-
pare the closeness of their output (test results) to 
their peers through statistical evaluation against 
an expected or target value. Participation in EQA is 
a key part of laboratory quality management and 
is essential for medical laboratories seeking ac-
creditation to the international standard ISO 15189: 
2012 Medical laboratories – Requirements for qual-
ity and competence (1). Through the provision of 
educational feedback and the sharing of best 
practice, as well as the assessment of individual 
laboratory performance, the EQA provider con-
tributes to quality improvement, as does active 
monitoring of EQA performance and early action 
on any adverse trend in performance by the par-
ticipating laboratory (2,3).
EQA programmes may be set up on a local, re-
gional, national or international basis and there 
are advantages and disadvantages to each of 
these. A local or regional service is generally more 
responsive and gives more rapid turnaround of re-
ports; however, it may not be as statistically robust 
as a national or international service and hence 
less able to give as good an overview of the state 
of the art of laboratory performance. For specialist 
tests or countries with relatively few testing sites, 
an international service may be the only option to 
provide a sufficient number of participants.
Accreditation of EQA providers is to the interna-
tional ISO 17043:2010 Conformity assessment –
General requirements for proficiency testing 
standard (4). An effective EQA programme will 
demonstrate the following key principles:
•	 Frequent distributions
•	 Commutable assay material, i.e. which displays 
the same inter-assay properties as clinical speci-
mens when tested by different methods or in-
struments
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•	 Stable, homogeneous specimens, which re-
semble and can be handled in the same way as 
clinical specimens where practicable
•	 Reliable, valid target values traceable to certi-
fied reference materials where available
•	 Rapid feedback of performance information to 
participating laboratories
•	 Structured, informative and intelligible reports
The complete blood count (CBC) is one of the 
most frequently requested tests in laboratory 
medicine, performed using robust but complex 
technologies that utilise impedance and light scat-
tering techniques to differentiate and count sus-
pended particles (cells) on the basis of their size 
and physical characteristics. These technologies 
are optimised to produce comparable results us-
ing fresh, anticoagulated whole blood tested as 
soon as possible after collection. The CBC parame-
ters covered by EQA vary by provider and scheme 
design but may include haemoglobin concentra-
tion (Hb), red blood cell count (RBC), haematocrit 
(Hct) or packed cell volume (PCV), mean cell vol-
ume (MCV), mean cell haemoglobin (MCH), mean 
cell haemoglobin concentration (MCHC), white 
blood cell count (WBC) and platelet count. To this 
may be added the automated differential white 
blood cell count, either three part (granulocyte, 
lymphocyte and monocyte counts) or five part 
(neutrophil, lymphocyte, monocyte, eosinophil 
and basophil counts) according to the properties 
of the analyser, the nucleated red blood cell count 
and other parameters, for example the red cell dis-
tribution width (RDW) and mean platelet volume 
(MPV).  
The availability and choice of assay material is a 
key factor in the provision of analytical phase EQA; 
without an adequate supply of good quality assay 
material, the frequency of distributions and the 
determination of a valid target value are compro-
mised. This article reviews the choices of assay ma-
terial available for use in the external quality as-
sessment of automated cell counting in haematol-
ogy and the influence that these choices may have 
on performance assessment and EQA scheme de-
sign. 
The ideal assay material for automated 
cell counting external quality assessment
The EQA provider has a demanding list of require-
ments for assay material (5). Whole blood from 
which the EQA samples are prepared must be eth-
ically sourced and comply with all legislation ap-
plicable to both the EQA provider and the recipi-
ent. It should be available in sufficient volume and 
at a time or frequency convenient for the EQA 
rounds, free of pathogens (unless detection of 
these is the objective of the EQA scheme), practi-
cal to handle and available at a price that is accept-
able to participating laboratories. The prepared 
material must homogeneous, stable both in tran-
sit and for the duration of the assay cycle and com-
mutable, where possible. The provision of speci-
mens from more than one assay material pool at 
each distribution is desirable as it allows the EQA 
provider to test analyser performance at different 
analyte concentrations in the same testing round, 
for  example allowing the assessment of very low 
level platelet counting without compromising the 
performance assessment of counts in the ‘normal’ 
range. Comparison of the results from more than 
one specimen in an EQA round also gives the EQA 
provider additional information on whether an 
out-of-consensus result reflects a true problem of 
analyser performance, one of sample handling by 
the participant (e.g. inconsistent mixing) or may 
have resulted from deterioration of EQA material 
in transit.
The participant’s requirements are similar but the 
participant emphasises the desire for a specimen 
that resembles clinical samples as closely as possi-
ble, especially in terms of how it is handled in the 
laboratory. Therefore, the ideal is a material of suf-
ficient volume and composition to allow it to be 
entered directly into specimen processing with as 
little special handling as possible. CBC material 
should be provided in a container that allows it to 
be sampled in the same way as clinical material, 
i.e. in a vial with a pierceable cap, which can be 
sampled in a ‘closed’ mode, and able to be pro-
cessed in the same counting mode using the same 
algorithms as patients’ samples.  The material 
above all should be clinically relevant, covering 
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clinical decision points, testing the full linearity of 
the machine or method and include analyte con-
centrations in both routine and pathological or 
disease states during a full series of EQA cycles.
EQA materials are excluded from the European 
Union directive that regulates the production of 
in-vitro medical diagnostic devices (6), meaning 
that their production does not have to meet the 
same production standards as diagnostic kits, in-
struments and other devices used in diagnostic lab-
oratories; however, demonstration of their fitness 
for purpose is an essential component of the ac-
creditation of the EQA provider to ISO17043 (4). This 
fitness for purpose should include the demonstra-
tion of the stability of the assay material in transit, 
e.g. by testing material circulated by post and re-
turned to the EQA provider for testing, tracking 
the temperature of the assay material in transit 
and understanding how this may affect the mate-
rial stability, and the statistical review of the results 
returned by location or transit time/conditions. If 
the transport conditions are likely to be incompat-
ible with the stability of the assay material, the 
EQA provider will either have to take preventative 
action, e.g. by the use of temperature controlled 
distribution networks or courier delivery, or re-
strict participation from locations that are likely to 
be adversely affected. The deterioration of assay 
material in transit must always be considered as a 
possible cause of an out of consensus EQA result.
Traceability and commutability in 
automated cell counting
Metrological traceability is the means by which 
laboratory results can be made comparable even 
where different calibration materials or methods 
of measurement are used.  International standards 
applicable to EQA require assay material to be as 
close to patients’ samples as possible, traceable to 
a certified reference material (CRM) or certified ref-
erence method (where available) and commutable 
in the event that the EQA scheme is to be used for 
inter-method comparison (4,7,8). A CRM is a mate-
rial used for calibration, method development or 
traceability that is certified as meeting the require-
ments in terms of homogeneity, stability and char-
acterisation of the measurand specified in the rel-
evant ISO standards. Materials that have been as-
sessed as meeting these criteria and their produc-
ers are listed in the catalogues published by the 
Joint Research Centre (JRC) of the European Union, 
the European Reference Material (ERM) co-opera-
tion and also the National Institute for Standards 
and Technology (NIST) in the United States of 
America for materials they produce (9-11).  
The Joint Committee on Traceability in Laboratory 
Medicine (JCTLM) provides a searchable database 
of certified reference materials and measurement 
methods/procedures to which the values of other 
standards, calibrators, controls or reference mate-
rials can be traced through an unbroken chain of 
calibrations (12). The stability of the cellular com-
ponents of blood and the rapidly changing nature 
of counting technology mean that higher order 
reference materials and methods for automated 
cell counting are very few, posing a challenge to 
the provision of traceable EQA assay material. At 
the time of writing, the only applicable JCTLM-list-
ed CRM is the haemoglobincyanide material (BCR-
522, haemoglobincyanide) produced by the Insti-
tute for Reference Materials and Measurements 
(IRMM), available from the JRC catalogue and the 
only JCTLM-listed certified reference method in 
automated cell counting is the flow cytometric 
method for platelet counting, published in part 5 
of the German national standard DIN 58932 (9,13). 
The DIN 58932 standard is published in several 
parts, which cover reference procedures for the 
determination of the concentration of other blood 
corpuscles, for example part 3 for the determina-
tion of the concentration of erythrocytes (14). Oth-
er recommended methods may be published by 
guidelines or professional organisations, for exam-
ple the International Council for Standardization in 
Haematology (ICSH) reference method for haemo-
globinometry (15), reflecting the best practice 
available.
The use of EDTA anticoagulated blood as 
EQA assay material
The sample of choice for blood counting is fresh, 
whole blood anticoagulated with the di-potassi-
Biochemia Medica 2017;27(1):63–72  http://doi.org/10.11613/BM.2017.008 
66
De la Salle B. Haematology EQA material
um, tri-potassium or di-sodium salt of ethylenedi-
aminetetra-acetic acid (EDTA) (16,17), which main-
tains the size, integrity and appearance of cellular 
blood components and provides material that is 
commutable across different automated cell 
counting platforms. The stability of cellular com-
ponents in EDTA for automated counting is limit-
ed: Hb concentration and RBC have been shown 
to be stable for up to 72 hours, automated total 
and differential white blood count for 24 hours (or 
longer, depending on analyser type) and platelet 
count stable for the same period (18,19). Swelling 
of red cells in EDTA will result in an increase in the 
MCV and haematocrit within 12 hours of collec-
tion. Blood anticoagulated in EDTA is of limited 
value for the measurement of mean platelet vol-
ume (MPV) due to swelling of platelets unless the 
sample is processed within 1 to 2 hours of vene-
section (20).  
Although EDTA-anticoagulated blood is inexpen-
sive and easily available in the laboratory either as 
surplus patients’ samples or from volunteer do-
nors, its limited stability make it impractical for au-
tomated counting EQA provision. In addition, sur-
plus patients’ material is available in relatively 
small individual samples of 3 to 4.5 mL volume 
and potential ABO blood group incompatibility 
precludes preparing larger volumes through pool-
ing. The infectious status of the samples is gener-
ally unknown. Blood donation bags containing 
EDTA as anticoagulant (e.g. di-potassium EDTA at a 
concentration of 1.5 – 2.2 mg/mL of blood) can be 
prepared for the venesection of a volunteer donor 
under appropriate medical supervision; however, 
the rapid deterioration of blood cells in EDTA 
means that the usefulness of a large volume of 
EDTA anticoagulated blood for EQA purposes is 
limited, except perhaps for a specifically designed 
inter-instrument or inter-laboratory comparison 
study.
The use of fresh EDTA blood, surplus to diagnostic 
testing requirements as assay material in quality 
assessment is suitable for ‘same day’ inter-instru-
ment or inter-laboratory testing arrangements 
within a laboratory network or geographically 
conveniently located testing sites; however, it is 
unsuitable for CBC EQA on a wider basis. Many 
EQA providers offer stained peripheral blood films, 
either on glass slides or as digital images, for as-
sessment of blood film morphology and manual 
white blood cell differential as part of their basic 
haematology provision. Blood cell morphology is 
maintained for several hours in EDTA, allowing the 
preparation of good quality stained blood films 
for microscopic examination (21). A fresh 3 to 5 ml 
EDTA patient’s sample is sufficient for the prepara-
tion of several hundred blood films, which will re-
main stable for long periods of time once fixed 
and stained using a standard haematology stain-
ing method for blood cell morphology, e.g. meth-
anol fixation followed by staining with May Grun-
wald-Giemsa, or a Wrights stain.
The use of citrate phosphate dextrose 
anticoagulated blood as assay material
Donated blood taken into citrate phosphate dex-
trose (CPD) blood donation bags is a practical op-
tion as bulk, raw material for the preparation of au-
tomated counting EQA material. A full blood do-
nation of approximately 475 mL provides 150 sam-
ples of 3 mL each and larger batches of specimens 
can be produced relatively easily by pooling ABO 
compatible blood. The EQA provider has two main 
sources of CPD-anticoagulated, human whole 
blood: local volunteers (usually members of the 
EQA service staff) or donations obtained from a 
national blood transfusion service. A major ethical 
concern regarding staff volunteers is undue influ-
ence from the employer, i.e. some staff may feel 
pressurised to volunteer as they may worry about 
potential adverse perception or repercussion from 
the employer if the refuse to donate. Venesection 
must be done under medical supervision in a suit-
ably equipped facility such as a blood donor cen-
tre or haematology ward. The volume of blood 
available from one individual is limited to a single 
unit donation at a time and the preparation of a 
larger pool by combining donations is reliant on 
the availability of ABO group-compatible individu-
als on the staff.
The use of whole blood and blood components 
obtained from anonymised donors through a na-
tional blood transfusion service is a sustainable 
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source of raw material but must be approved by 
the transfusion service. Donors must be aware and 
give consent for their blood to be used for non-
clinical issue purposes, such as quality assurance, 
rather than therapeutic donation. Blood donors 
are screened by the donation service for recog-
nised blood-borne infectious agents, reducing the 
risk of the EQA provider unknowingly exposing a 
large number of testing sites and the delivery ser-
vices to any hazard contained in the material. 
Since blood for therapeutic donation is routinely 
leuco-depleted and separated into its component 
parts during preparation, the supply of whole 
blood, especially if non-leuco-depleted, will re-
quire special arrangement with the blood transfu-
sion service.
If blood is given altruistically without payment to 
the donor, which is the norm in many national do-
nation services, the EQA provider must consider 
the terms and conditions under which any charges 
are made for the EQA service. Good practice is that 
no charge is made for the EQA assay material and 
that fees are charged on a not-for-profit basis for 
the associated preparation, distribution and data 
analysis services only.
CPD anticoagulant maintains red cells for 21 days 
or more for Hb concentration and RBC (22). Total 
WBC or leucocyte counts are stable for several 
days but the features of the cells deteriorate rap-
idly with the same storage artefacts seen as in 
EDTA, meaning that the material is not suitable for 
automated white cell differential unless used 
promptly after venesection. Platelets are also of 
limited stability. Blood from ABO-compatible do-
nors may be pooled to make a large assay material 
pool, although the maintenance of homogeneity 
during preparation and bottling becomes a great-
er challenge the greater the volume of the pool, 
requiring specialist mixing and bottling equip-
ment (23). If used without further stabilisation, 
CPD anticoagulated material is commutable across 
different analyser platforms although early studies 
noted variation in the response of different count-
ing technologies (24).
CPD anticoagulated blood used without further 
stabilisation requires distribution within 24 hours 
of venesection and analysis upon receipt by the 
participating laboratory to ensure good compara-
bility of results between participants. This imposes 
restrictions on the scope of EQA service. The geo-
graphical range of the distribution is limited by the 
efficiency and cost of postal or courier service and 
the stability of the material poses a challenge for 
the testing of remote sites, those with restricted 
opening times, point of care testing facilities or 
out-of-hours services. It is not possible to provide 
material for re-testing by participants or to replace 
samples that are received damaged or accidental-
ly discarded or damaged in the laboratory.  To re-
move the potential of adverse impact on the par-
ticipant of sample deterioration, the EQA provider 
may ask participants to analyse the material on the 
same day or analyse the results returned against 
the testing date to review the influence of transit 
and storage.
Volunteer donors, whether recruited from staff or 
the blood donation service, must be healthy to 
donate. A limitation of using healthy volunteers is 
the potentially limited range of analyte concentra-
tion obtained, which may not test the pathological 
range. The Hb concentration and the counts of the 
cellular components can be adjusted before bot-
tling to simulate pathological conditions but ma-
nipulation will extend the preparation time of the 
assay material, delaying its distribution.
An EQA provider with a comprehensive range of 
surveys available may aim to consolidate as many 
different EQA surveys types as possible in the 
same distribution package to reduce delivery 
costs. Consolidated packing arrangements may 
conflict with the necessity for rapid distribution.
Donated blood taken into CPD from volunteers 
and used without further stabilisation is suitable 
for smaller scale national or regional EQA schemes 
with limited numbers of participants and access to 
good postal or courier delivery services.
The use of animal blood as EQA assay 
material
Animal blood has the potential for use as EQA as-
say material. For example, donkey blood has a 
mean cell volume at the low end of the human 
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physiological range and hence mimics MCV results 
found in microcytic anaemia (25). Sheep blood ap-
pears naturally deficient in glucose-6-phosphate 
dehydrogenase activity in human terms and can 
be used as a source of deficient assay material (26). 
The venesection of living animals is not without 
ethical considerations related to animal welfare 
and may require the same level of licensing as the 
use of animals in clinical research. Commercial 
supply of blood from a limited range of domestic 
animal species is available in sufficient volumes for 
use in EQA and non-human blood or blood com-
ponents may form part of commercial EQA assay 
materials, standards and controls.
Stabilised whole blood as EQA assay 
material
Initial CBC EQA material did not contain intact red 
cells but was prepared from dilutions of 
haemolysate for the measurement of haemoglo-
bin concentration with fixed avian cells (pseudo-
leucocytes) and fixed platelets. This material is 
very stable in transit but is suitable only for use 
with basic or manual techniques. Although this 
material cannot performance assess the measure-
ment of red cell indices or automated differential 
count, it is cost effective and may still have an ap-
plication in resource-limited countries (27). This 
material is not suitable for the performance assess-
ment of the full range of blood count parameters 
produced by automated cell counters.
The stability of whole blood for use as automated 
counting EQA assay material can be prolonged by 
chemical stabilisation. Partial fixation of whole 
blood with aldehydes is possible for the EQA pro-
vider to undertake in-house and produces an as-
say material stable for several weeks (28,29). Large 
volumes of assay material can be prepared by 
pooling ABO-compatible blood components but 
the fixation results in changes in the cell mem-
branes that render the blood non-commutable 
across different analyser platforms, especially for 
MCV, WBC and platelet count (30). Haemoglobin 
concentration, Hct and RBC can be manipulated 
prior to stabilisation by mixing whole blood and 
red cell concentrates, plasma reduction or the ad-
dition of ABO-compatible fresh frozen plasma. 
White blood count and platelet count can be ma-
nipulated by mixing leuco-depleted and non-leu-
co-depleted blood with the addition of buffy-coat 
residues or platelet concentrates. The use of blood 
components that would otherwise be suitable for 
therapeutic transfusion may represent a conflict of 
interest and the EQA organiser must engage the 
support of the national blood transfusion service 
to ensure sustainability of supply. The preparation 
of stabilised CBC assay material by the EQA provid-
er requires technical skill, experience and the avail-
ability of good laboratory facilities but is a cost ef-
fective means to produce assay material for a large 
number of participating laboratories. Despite the 
lack of full commutability across all platforms, the 
levels of most of the analytes are within the con-
trol of the EQA organiser and allow the organiser 
to challenge participants at critical analyte con-
centrations, for example, at decision levels for 
platelet transfusion and can highlight state-of-the-
art variability in other parameters (31-33). The 
same material is distributed to all platforms in a 
single survey and it is possible to associate the 
same clinical scenarios with the material and re-
port these back to the participants for educational 
purposes. This stabilised material is generally un-
suitable for differential white blood count as the 
fixation alters the cell membrane and hence how 
the cells react in different counting methodolo-
gies, also white cells deteriorate in the time re-
quired for virological testing by the transfusion 
service (up to 72 hours). Even within the same in-
strument group, it may be necessary to know what 
mode has been used for WBC and platelet counts 
(optical, impedance, fluorescent or immunologi-
cal) or to require the participant to report results 
from one mode only. This precludes allowing the 
instrument software to select the mode according 
to the count, where more than one mode is avail-
able, as it would for patients’ samples. The proce-
dures used in the preparation of assay material, 
e.g. pooling, mixing, centrifugation etc., may result 
in the activation of platelets and interfere with 
non-impedance platelet counting methods (34,35).
EQA assay material for reticulocyte counting can 
be prepared using the same methods as used for 
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CBC assay material, as the fixation arrests the retic-
ulocyte maturation, producing a material suitable 
although not commutable for most automated 
counters (note that this material is not suitable for 
Beckman-Coulter analysers, at the time of writing). 
There remains a challenge to produce material 
with a raised reticulocyte count from whole blood 
obtained from healthy donors; the reticulocyte 
count can be boosted with the use of buffy coat 
residues but the levels achieved still do not reach 
those found in a commercial high-level reticulo-
cyte control.
Commercially prepared, whole blood assay mate-
rial for blood cell counting is available (major glob-
al suppliers are Streck, Inc (Omaha, NE) (36) and 
R&D Systems, Inc (Minneapolis, MN) (37) and is 
widely used in EQA. Commercial material has a 
number of advantages for the EQA provider: it is 
stable for long periods of time, requires no labora-
tory facilities other than for storage, is available in 
the quantities required, is sustainable and the 
demonstration of ethical compliance is the re-
sponsibility of the manufacturer. However, the ma-
terial may not be commutable across instrument 
groups for all parameters of the extended CBC and 
may require special handling, e.g. analysis in a 
quality control (QC) mode. The EQA organiser is 
able to choose the range of analyte levels but the 
choice is restricted to those produced by the man-
ufacturer of the material and may not allow the 
specification of particularly low or high cell con-
centrations. The material is supplied with a certifi-
cate of analysis but its exact formulation and pro-
duction methods are a matter of commercial con-
fidence. The materials are frequently the same as 
those used for routine IQC materials and are de-
signed to fulfil a tri-level control function. Where 
commercial assay materials are the same as those 
used as IQC material, it is essential that the EQA or-
ganiser specifies that the lots provided for EQA are 
different from any in circulation as IQC material 
during the time of the EQA cycle. Despite these 
drawbacks, commercial material may be the only 
choice for the EQA provider for some automated 
counting parameters, e.g. automated differential 
leucocyte count or raised reticulocyte count, 
where the preparation of the material is beyond 
the scope of the EQA provider and may require the 
use of artificial particles or animal cells.
Stabilised blood, whether prepared by the EQA 
provider or purchased commercially, is suitable for 
schemes with large numbers of participating labo-
ratories and where delivery times may be pro-
longed, for example where services are provided 
internationally. Preparation of stabilised assay ma-
terial in-house gives the EQA provider greatest 
control over analyte concentrations and hence the 
ability to respond to perceived performance 
trends but is not suitable for the performance as-
sessment of automated differential leucocyte 
counting and or reticulocyte counting at high lev-
els and for all technologies. Commercially pre-
pared, whole blood specimens may be the materi-
als of choice for an international scheme or one 
scheme with large participant numbers. However, 
it is significantly more expensive than many of the 
other options and this may preclude its use by 
some providers.
Discussion and conclusions
A demonstrated lack of commutability of assay ma-
terial requires grouping of instruments for perfor-
mance analysis. These groupings become more 
complex where instrument group specific material 
types are supplied, e.g. as may be required for au-
tomated differential leucocyte counting, and entail 
grouping by material type with additional sub-
grouping by instrument model in some instances. 
The EQA organiser must take into account informa-
tion and advice from the manufacturers of both 
the assay material and the instruments and empiri-
cal evidence from participants’ results to decide on 
the correct instrument grouping for analysis.  
The analytical performance for most of the consol-
idated parameters in the CBC is recognised as very 
good, therefore the distribution of EQA material 
that focuses solely on the normal range for Hb 
concentration, WBC, RBC etc. to fully automated 
laboratories may be of questionable clinical utility, 
failing to provide challenges at the levels of clinical 
decision making and giving a false sense of securi-
ty in performance (38). The use of non-commuta-
ble material however may have the same impact, 
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where instrument grouping that results in only 
comparing analysers on a ‘like with like’ basis may 
not reflect true variation in performance. Immedi-
ate decisions are made on the basis of the results of 
the CBC, especially where the instruments are 
placed in acute care situations, and the provision of 
EQA for point-of-care instruments as well as those 
in automated laboratories is essential (39). Whether 
or not the scheme design includes POCT-placed in-
struments will affect the choice of assay material, 
since these instruments may not be located to al-
low the immediate testing of fresh material, for ex-
ample they may be in remote sites, in clinics that 
do not operate a daily service or in community 
based services or emergency vehicles. EQA materi-
al capable of demonstrating comparability be-
tween different instruments is likely to become 
more difficult in the future with the introduction of 
new cell counting technologies, for example, im-
age analysis as used by Bloodhound™ technology 
and point-of-care instruments utilising cartridge 
based microfluidics (40-42). For POCT methodolo-
gies designed for use with fresh, fingerprick blood, 
the haemoglobin assay method may not convert 
methaemoglobin to a measurable form, making 
this an interfering substance in stored EQA assay 
material and requiring the separate grouping of 
instruments for performance assessment.
Where the numbers of registered participants in a 
group is small (i.e. fewer than the ideal 10-20 in-
struments for statistical analysis), it is possible to 
evaluate performance against the all methods 
mean target value, if all are using the same mate-
rial, even if this is not commutable. This is not ideal 
as the instrument may have a bias against this tar-
get that is due solely to the nature of the assay ma-
terial; however, if the instrument’s performance is 
consistent in that bias, it is still possible for its per-
formance to be assessed if the EQA organiser re-
views and defines individual minimum acceptable 
performance limits for the instrument and the var-
iability that is allowed. This approach is not possi-
ble where instrument-specific assay material is dis-
tributed. Particular EQA statistics have been de-
scribed to assess performance for scheme with 
small numbers of participants (43).
Other parameters of the extended CBC are finding 
increasing clinical application, for example the re-
ticulocyte haemoglobin concentration in the diag-
nosis of iron deficiency in patients with chronic re-
nal disease (44-46). Laboratories seeking to in-
clude these new parameters in their ISO15189 ac-
creditation scope will have to demonstrate inter-
laboratory comparability for their results and are 
likely to prefer EQA provision to developing alter-
native approaches such as sample exchange.
External quality assessment for the complete 
blood count is an established part of comprehen-
sive medical EQA provision. The ideal assay mate-
rial that resembles clinical material and is commut-
able across all analyser platforms for all parame-
ters in automated counting does not exist and the 
EQA provider must select the most ‘fit for purpose’ 
for the objectives of the scheme and be aware of 
the impact that this may have on the evaluation of 
participating laboratories’ performance. The ‘fit for 
purpose’ criteria must take into account the range 
of analysers and types of testing sites participating 
in the scheme, as well as the transport conditions 
to which the assay material will be exposed, to en-
sure continued clinical utility of the EQA service.
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